Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

A pilot clinical trial (NCT03519308) was conducted to evaluate perioperative chemotherapy [nab-paclitaxel, gemcitabine, and cisplatin (NGC)] plus nivolumab, with or without synthetic vitamin D (paricalcitol) in resectable pancreatic ductal adenocarcinoma (PDAC).

Preclinical studies were designed with statistical power to match the experimental regimen and compare NGC only with NGC plus synthetic vitamin D [calcipotriol (Cal)] or losartan (Losa; an antihypertensive medication).

Multiparametric MRI and molecular profiling were integrated to assess treatment-induced effects on stroma, including capillary perfusion and density, matrix collagen content, fibroblast activation protein (FAP) levels and transcriptome changes.

Who Took Part

The age groups tagged for this paper are older adults, both men and women.

Molecular subtyping was applied to enroll patients with epithelial subtype PDAC.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Genetically engineered PDAC models (KrasG12D;Trp53R172H;Pdx1-Cre mice, N = 140) were randomized to NGC only and combined therapies.

What Was Measured

Topics PubMed links to this paper include Pancreatic Neoplasms, Mice, Carcinoma, Pancreatic Ductal, Antineoplastic Combined Chemotherapy Protocols, Ergocalciferols, Magnetic Resonance Imaging and Pilot Projects.

What This Means in Plain Language

The paper is a randomized and pilot study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Cancer research communications), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.